Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer ; volume:14 ; number:1 ; day:6 ; month:1 ; year:2012 ; pages:1-11 ; date:2.2012
Breast cancer research ; 14, Heft 1 (6.1.2012), 1-11, 2.2012
- Urheber
-
Aleskandarany, Mohammed A.
- Beteiligte Personen und Organisationen
-
Green, Andrew R.
Benhasouna, Ahmed A.
Barros, Fabricio F.
Neal, Keith
Reis-Filho, Jorge S.
Ellis, Ian O.
Rakha, Emad A.
SpringerLink (Online service)
- DOI
-
10.1186/bcr3084
- URN
-
urn:nbn:de:1111-2016032414258
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Aleskandarany, Mohammed A.
- Green, Andrew R.
- Benhasouna, Ahmed A.
- Barros, Fabricio F.
- Neal, Keith
- Reis-Filho, Jorge S.
- Ellis, Ian O.
- Rakha, Emad A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients